[u'-----BEGIN PRIVACY-ENHANCED MESSAGE-----\nProc-Type: 2001,MIC-CLEAR\nOriginator-Name: webmaster@www.sec.gov\nOriginator-Key-Asymmetric:\n MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen\n TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB\nMIC-Info: RSA-MD5,RSA,\n CMHrtKp28xe3Oe0G0yj21KtyMoAnJ490sywHRQNLHYw2jl29Mt6C1+S39qqj05C8\n TvzMLLOZJBQp7/WWt66pPA==\n\n', u'0001001277-04-000396.txt : 20040910\n', u'0001001277-04-000396.hdr.sgml : 20040910\n', u'20040910135507\nACCESSION NUMBER:\t\t0001001277-04-000396\nCONFORMED SUBMISSION TYPE:\t8-K\nPUBLIC DOCUMENT COUNT:\t\t2\nCONFORMED PERIOD OF REPORT:\t20040910\nITEM INFORMATION:\t\tResults of Operations and Financial Condition\nITEM INFORMATION:\t\tFinancial Statements and Exhibits\nFILED AS OF DATE:\t\t20040910\nDATE AS OF CHANGE:\t\t20040910\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tTHERMOGENESIS CORP\n\t\tCENTRAL INDEX KEY:\t\t\t0000811212\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tLABORATORY APPARATUS & FURNITURE [3821]\n\t\tIRS NUMBER:\t\t\t\t943018487\n\t\tSTATE OF INCORPORATION:\t\t\tDE\n\t\tFISCAL YEAR END:\t\t\t0630\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t8-K\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t333-82900\n\t\tFILM NUMBER:\t\t041024670\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t2711 CITRUS ROAD\n\t\tCITY:\t\t\tRANCHO CORDOVA\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t95742\n\t\tBUSINESS PHONE:\t\t9168585100\n\n\tMAIL ADDRESS:\t\n\t\tSTREET 1:\t\t2711 CITRUS ROAD\n\t\tCITY:\t\t\tRANCHO CORDOVA\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t95742\n\n\tFORMER COMPANY:\t\n\t\tFORMER CONFORMED NAME:\tINSTA COOL INC OF NORTH AMERICA\n\t\tDATE OF NAME CHANGE:\t19920703\n', u'\n', u'\n', u'8-K\n', u'1\n', u'pressrelease.txt\n', u"\n\n\n                                  UNITED STATES\n                       SECURITIES AND EXCHANGE COMMISSION\n                             Washington, D.C. 20549\n\n                                    FORM 8-K\n\n                                 CURRENT REPORT\n     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934\n\n      Date of Report (Date of earliest event reported): September 10, 2004\n\n\n\n                               THERMOGENESIS CORP.\n             (Exact name of registrant as specified in its charter)\n\n\n\n               Delaware                  0-16375                94-3018487\n               ---------                 --------               ----------\n(State or other jurisdiction of      (Commission File        (I.R.S. Employer\n incorporation or organization)          Number)             Identification No.)\n\n                                2711 Citrus Road\n                        Rancho Cordova, California 95742\n                        --------------------------------\n    (Address and telephone number of principal executive offices) (Zip Code)\n\n                                 (916) 858-5100\n                                 --------------\n              (Registrant's telephone number, including area code)\n\nCheck  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to\nsimultaneously  satisfy the filing obligation of the registrant under any of the\nfollowing provisions (see General Instruction A.2. below):\n\n[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR\n    230.425)\n[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act\n    (17 CFR 240.14a-12)\n[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange\n    Act (17 CFR 240.14d-2(b))\n[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange\n    Act (17 CFR 240.13e-4(c))\n\n\n\n", u'\n\n\n\nSection 2 - Financial Information\n- ---------------------------------\n\nItem 2.02 Results of Operations and Financial Condition.\n\n     ThermoGenesis  Corp.  announced  its results for the fiscal year ended June\n30, 2004 on the attached press release.\n\nSection 9 - Financial Statements and Exhibits\n- ---------------------------------------------\n\nItem 9.01 Financial Statements and Exhibits.\n\n         Exhibit No.       Exhibit Description\n         -----------       -------------------\n\n         99                Press release announcing fiscal June 30, 2004 year\n                           end results\n\n\n\n\n', u'\n\n\n                                    SIGNATURE\n\n     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the\nregistrant  has duly  caused  this  report  to be  signed  on its  behalf by the\nundersigned hereunto duly authorized.\n\n\n                                    THERMOGENESIS CORP.,\n                                    a Delaware Corporation\n\n\nDated:  September 10, 2004          /s/ Renee Ruecker\n        ------------------          --------------------------------------------\n                                    Renee Ruecker,\n                                    Chief Financial Officer\n\n', u'\n', u'\n', u'\n', u'EX-99\n', u'2\n', u'exhibit99.txt\n', u'\n\n                  THERMOGENESIS CORP. ANNOUNCES FOURTH QUARTER\n                              AND YEAR END RESULTS\n\n               Company Achieves Record Quarter and Annual Revenues\n                           Led By BioArchive(R) Sales\n\n\nRancho Cordova,  California  (September 10, 2004) - THERMOGENESIS CORP. (Nasdaq:\nKOOL) today  announced  results for it\'s fourth  quarter and year ended June 30,\n2004.  Net  revenues  for the  quarter  ended June 30,  2004,  increased  25% to\n$3,636,000,  compared to $2,898,000  for the fourth  quarter of fiscal 2003. For\nthe year ended June 30,  2004,  the  Company\'s  net  revenues  increased  14% to\n$11,646,000 compared to $10,187,000 for the prior year. The gross profit for the\nfourth quarter was  $1,244,000 or 34% of net revenues  compared to $1,008,000 or\n35% for the  fourth  quarter  ended June 30,  2003.  For the year ended June 30,\n2004, the gross profit  increased to $3,802,000 or 33% compared to $2,287,000 or\n22% for the prior year.\n\nOur net loss for the quarter  ended June 30, 2004,  was  $1,097,000 or $0.02 per\nbasic and diluted  share  compared to a $991,000 net loss of $0.03 per basic and\ndiluted share for the quarter  ended June 30, 2003.  For the year ended June 30,\n2004,  the net loss was  $4,777,000  or $0.11  per basic and  diluted  share,  a\ndecrease from $5,603,000 or $0.15 per basic and diluted share for the year ended\nJune 30, 2003.\n\nThe Company  posted  it\'s  highest  revenues  since it\'s  inception,  led by the\nBioArchive  product  line which  generated  $7,745,000  in revenues for the year\nended June 30, 2004, an increase of  $2,297,000 or 42% over the prior year.  The\nCompany sold 26 devices in the year ended June 30,  2004,  versus 20 in the year\nended June 30,  2003.  The Company  attributes  the  increase to the infusion of\ngovernment  funding in Japan and  Moscow  and the  growth of private  cord blood\nbanking in Asia.\n\n"The increase in the annual gross profit margin  demonstrates the success of the\nrestructuring plan implemented in the last quarter of fiscal 2003", stated Kevin\nSimpson,  President  and  Chief  Operating  Officer.  "This  restructuring  plan\n\n', u'\n\nincluded  an increase in volume and  selling  prices of the  BioArchive  product\nline,  reduction of our in-house  costs of  manufacturing,  and an array of cost\nreduction activities to improve our operating margin."\n\nThe Company  reported a cash  balance of $16.6  million  and working  capital of\n$19.8  million  at June 30,  2004  compared  to $6.8  million  of cash and $10.4\nmillion of working capital at June 30, 2003.\n\n"I am  very  pleased  with  our  results  for  fiscal  2004,  specifically,  our\nachievement  of  record   revenues  and  gross  profit,   and  a   significantly\nstrengthened   balance  sheet",   said  Philip  Coelho,   Chairman  and  CEO  of\nThermoGenesis.  "It appears that our  BioArchive  product  platform is achieving\ninternational  market  acceptance  and we hope the same  trend  will  follow the\ncompletion  of the  CryoSeal  US  clinical  trial and  market  launch of product\nplatform extensions."\n\nCompany Conference Call\nManagement will host a conference call today, September 10, 2004 at 11:00 AM PDT\nto review the financial  results and other corporate  events,  followed by a Q&A\nsession. The call can be accessed by dialing:  (800) 860-2442 within the U.S. or\n(412) 858-4600  outside the U.S and giving the conference name  "THERMOGENESIS".\nParticipants  are  asked to call the  assigned  number  approximately  5 minutes\nbefore the  conference  call  begins.  A replay of the  conference  call will be\navailable  two hours  after the call for the  following  five  business  days by\ndialing:  (877) 344-7529 within the U.S. or (412) 317-0088  outside the U.S. and\nentering the following account number: 323 and the following  conference number:\n353367.\n\nAbout ThermoGenesis Corp.\nAfter extensive  research,  THERMOGENESIS  CORP.\'s newly  introduced  technology\nplatforms  lead the world in their ability to produce  biological  products from\nsingle units of blood.  Umbilical  cord blood banks are  utilizing the Company\'s\nBioArchive  System as an enabling  technology  for the  cryogenic  archiving  of\nhematopoietic  stem cell  units.  The  CryoSeal  FS  System  is used to  prepare\nautologous  hemostatic and adhesive  surgical  sealants from patient blood.  The\nCryoSeal  FS  System  is  currently  undergoing  a Phase  III  trial  and is not\n\n', u"\n\ncurrently sold in the U.S.  THERMOGENESIS  CORP. has been a leading  supplier of\nstate-of-the-art  Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and\nblood banks since 1992.\n\nThe statements contained in this release which are not historical facts are\nforward-looking statements that are subject to risks and uncertainties that\ncould cause actual results to differ materially from those expressed in the\nforward-looking statements, including, but not limited to, certain delays beyond\nthe Company's control with respect to market acceptance of new technologies and\nproducts, delays in testing and evaluation of products and other risks detailed\nfrom time to time in the Company's filings with the Securities and Exchange\nCommission.\n\n                         For More Information, Contact:\n                               THERMOGENESIS CORP.\n                        Renee M. Ruecker: (916) 858-5100\n                 or visit the web site at www.thermogenesis.com\n\n", u'\n                               THERMOGENESIS CORP.\n                            Condensed Balance Sheets\n                                    Unaudited\n', u'\n', u'\n', u' ', u' ', u"\n\n                                                                               June 30,                  June 30,\n                                                                                 2004                      2003\n                                                                           ---------------           -----------------\nASSETS\nCurrent assets:\n  Cash and cash equivalents                                                  $16,612,000                $6,815,000\n  Accounts receivable, net                                                     3,107,000                 2,014,000\n  Inventory                                                                    2,470,000                 2,650,000\n  Other current assets                                                           582,000                   820,000\n                                                                           ---------------           -----------------\n\n      Total current assets                                                    22,771,000                12,299,000\n\nEquipment, net                                                                 1,146,000                   442,000\n\nOther assets                                                                     197,000                    50,000\n\n                                                                             $24,114,000               $12,791,000\n                                                                           ===============           ================\n\nLIABILITIES AND STOCKHOLDERS' EQUITY\n\nCurrent liabilities:\n  Accounts payable                                                            $1,709,000                $1,165,000\n  Other current liabilities                                                    1,264,000                   769,000\n                                                                           ---------------           -----------------\n\n      Total current liabilities                                                2,973,000                 1,934,000\n\nLong-term liabilities                                                            173,000                   283,000\n\nStockholders' equity                                                          20,968,000                10,574,000\n                                                                           ---------------           -----------------\n\n                                                                             $24,114,000               $12,791,000\n                                                                           ===============           ================\n", u'\n', u'\n', u'\n', u'\n-----END PRIVACY-ENHANCED MESSAGE-----\n']